2. What a Partner‑Sponsored Study Means for UEEC’s PMA Path
A. Independence = FDA Confidence
The FDA’s biggest issue with UEEC’s earlier trial was lack of independence.
A partner‑sponsored study solves that by ensuring:
The Sponsor controls the trial
The CRO reports to the Sponsor, not UEEC
UEEC cannot influence data collection or analysis
This dramatically increases the credibility of the resulting data.
B. UEEC Gets “Right of Reference”
UEEC will have an exclusive right of reference to all clinical data generated.
That means:
The partner runs the trial
UEEC owns the ability to use the results in its PMA
The partner cannot use the data for its own competing PMA
This is the ideal structure for UEEC.
C. Faster PMA Resubmission Path
Once the trial begins:
Enrollment → ~6–9 months
Follow‑up period → typically 30 days for hemostatic devices
Data analysis → ~3 months
PMA resubmission → immediately after data lock
If the study is clean and meets endpoints, UEEC could move rapidly toward approval.
D. Why FDA Likes This Approach
FDA gets:
A clean, independent dataset
A Sponsor with a proven track record
Reduced risk of protocol deviations
UEEC gets:
A credible path to approval
A partner with distribution and manufacturing capabilities
A potential future commercial ally
Bottom Line
UEEC has secured FDA approval to use an independent partner as the Sponsor for the new CelluSTAT clinical trial.
The identity of the partner has not yet been publicly disclosed, but the regulatory structure is approved and ready.
If you want, I can also map out:
A projected timeline to PMA approval
The likely profile of the unnamed partner
How this affects UEEC’s valuation or commercialization prospects
Just tell me which direction you want to go.
A. Independence = FDA Confidence
The FDA’s biggest issue with UEEC’s earlier trial was lack of independence.
A partner‑sponsored study solves that by ensuring:
The Sponsor controls the trial
The CRO reports to the Sponsor, not UEEC
UEEC cannot influence data collection or analysis
This dramatically increases the credibility of the resulting data.
B. UEEC Gets “Right of Reference”
UEEC will have an exclusive right of reference to all clinical data generated.
That means:
The partner runs the trial
UEEC owns the ability to use the results in its PMA
The partner cannot use the data for its own competing PMA
This is the ideal structure for UEEC.
C. Faster PMA Resubmission Path
Once the trial begins:
Enrollment → ~6–9 months
Follow‑up period → typically 30 days for hemostatic devices
Data analysis → ~3 months
PMA resubmission → immediately after data lock
If the study is clean and meets endpoints, UEEC could move rapidly toward approval.
D. Why FDA Likes This Approach
FDA gets:
A clean, independent dataset
A Sponsor with a proven track record
Reduced risk of protocol deviations
UEEC gets:
A credible path to approval
A partner with distribution and manufacturing capabilities
A potential future commercial ally
Bottom Line
UEEC has secured FDA approval to use an independent partner as the Sponsor for the new CelluSTAT clinical trial.
The identity of the partner has not yet been publicly disclosed, but the regulatory structure is approved and ready.
If you want, I can also map out:
A projected timeline to PMA approval
The likely profile of the unnamed partner
How this affects UEEC’s valuation or commercialization prospects
Just tell me which direction you want to go.
